Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Common Equity (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Common Equity for 4 consecutive years, with $284.3 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 39.32% to $284.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $284.3 million through Dec 2025, up 39.32% year-over-year, with the annual reading at $284.3 million for FY2025, 39.32% up from the prior year.
  • Common Equity for Q4 2025 was $284.3 million at LENZ Therapeutics, up from $193.9 million in the prior quarter.
  • The five-year high for Common Equity was $361.3 million in Q1 2022, with the low at -$69.6 million in Q3 2023.
  • Average Common Equity over 4 years is $168.1 million, with a median of $198.2 million recorded in 2024.
  • The sharpest move saw Common Equity crashed 121.98% in 2023, then skyrocketed 640.29% in 2024.
  • Over 4 years, Common Equity stood at -$24.2 million in 2022, then tumbled by 187.84% to -$69.6 million in 2023, then soared by 393.36% to $204.1 million in 2024, then soared by 39.32% to $284.3 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $284.3 million, $193.9 million, and $206.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.